Why access to weight loss injections in the UK is so unequal

Step 1: Understanding how NHS access is rationed by design

NICE recommended tirzepatide (Mounjaro) for NHS use in December 2024, but the rollout was never intended to be immediate or universal. NHS England built a phased structure: from June 2025, only adults with a BMI of 40 or above and four or more qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes) could access it through primary care. From June 2026, a second cohort opened the door slightly wider, to BMI 35–39.9 with four or more of those same conditions. A third phase, planned for around March 2027, will cover BMI 40 and above with three conditions.

That sequencing is deliberate: the NHS is managing supply, cost and prescribing capacity. But the practical effect is that two people with identical weight, health profile and clinical need may have entirely different experiences depending on which cohort they fall into and when they ask. If you want to understand whether the current criteria cover your situation, checking the full eligibility picture is a useful starting point.

Semaglutide (Wegovy) has been recommended by NICE since 2023, but only through specialist weight management services, and those services have their own waiting lists, which in some areas stretch considerably. NICE's appraisal of tirzepatide (TA1026) sets out the phased criteria in detail.

Step 2: Recognising the geographic and demographic layers of inequality

Even within the NHS phase that is currently active, access depends on your integrated care board. Some ICBs have been faster to implement the new GP prescribing arrangements introduced by the 2026/27 QOF contract; others have not yet stood up the wraparound diet and activity support that NHS guidance requires patients to receive alongside the medicine. Without that support structure in place locally, GPs in those areas cannot prescribe.

The ethnic-background adjustment in NICE's guidance is clinically grounded (cardiometabolic risk rises at lower BMIs in several South Asian, Chinese, Middle Eastern, Black African and African-Caribbean populations) but awareness of the adjustment among patients and, in some cases, clinicians remains inconsistent. People who would qualify under the corrected threshold may be told they do not meet it. That is an inequality that sits partly inside the system itself.

Geography creates a second layer. In rural areas, specialist weight management services may be further away or under-resourced. Deprivation compounds the picture: people in the most deprived communities carry the highest rates of obesity-related conditions but face the most barriers to treatment. NHS England's broader medicines-for-obesity programme acknowledges this explicitly, though translating acknowledgement into equitable access takes time.

Step 3: Where private treatment fits, and the inequality that creates too

Here is the part that can feel uncomfortable to say plainly. Private regulated routes exist legally. Adults who do not meet the current NHS thresholds, or who do not want to wait, can access Mounjaro or Wegovy through a GPhC-registered online pharmacy, following a clinical assessment by a GPhC-registered prescriber. That is a legitimate option, but it is only an option if you can afford it.

Mounjaro's UK private price has risen substantially since Eli Lilly adjusted its list price in September 2025; typical private monthly costs now range roughly £149–£375 depending on the dose and provider, as widely reported. If you are weighing up what is and is not included in that cost, the cost breakdown for weight loss injections on this site explains what a legitimate price should cover. For most people on lower incomes, that cost is simply not accessible. Private treatment does not solve the inequality problem; it sidesteps it for those with the means to do so.

That asymmetry matters. People who qualify medically but cannot afford private treatment are left waiting on a phased NHS system. People who can pay may not need to meet the same clinical thresholds, though a responsible prescriber will still decline if treatment is not clinically appropriate. If you are based locally and want to explore your options in person, our guide to weight loss injections in Hadleigh covers what is available through our clinic there, and the distinction between NHS and private routes is explained in full.

What this means in practice

If you are reading this because you have been told you do not qualify, or because the waiting list feels impossibly long, that frustration is entirely reasonable. The gap between clinical need and accessible treatment is real, and it is not your fault for noticing it.

A few things are worth knowing. First, the NHS criteria are actively evolving; a cohort that excludes you today may include you in 2027. Second, if your BMI is near a threshold, it is worth asking specifically whether the ethnic-background adjustment applies to you, your GP should know, and if they are unsure, NICE's published guidance is the reference. Third, if you are considering a private route, verify any online pharmacy on the GPhC register before providing personal or payment details; counterfeit pens sold through unverified channels are a documented risk, and the MHRA has issued repeated warnings on the subject.

The broader picture of weight loss injection provision in the UK is covered across the weight loss injections overview, and if you want a sense of the real-world results people have achieved, the weight loss injection success stories collected on this site are worth reading alongside the evidence on how well these treatments work. If you want to explore whether a private consultation is an option for you, check your eligibility with our prescribers, the consultation is free, there is no pressure, and a real clinician reviews your answers the same day.